Forest Labs Posts Earnings Miss
Forest Laboratories (FRX) missed earnings estimates for the second quarter of 2008 in light of a license fee but upped its full-year guidance Tuesday.
The drugmaker earned 71 cents a share, a 5% decrease from 75 cents a share in the year-ago quarter. Net income decreased 7% to $225.2 million from $241.1 million. Analysts surveyed by Thomson Financial were expecting 74 cents a share on revenue of $931 million.
Earnings were affected by a $70 million licensing charge (that equated to 15 cents a share net of tax) to Microbia for the right to co-develop and co-market constipation treatment linaclotide.
Research and development expenses increased 82% to $170.7 million during the quarter, including the $70 million licensing charge made in connection with the Microbia agreement.Quarterly revenue increased 8.5% to $919 million from $847 million in the year-ago period. Sales of Lexapro for the treatment of depression and anxiety in adults totaled $559.1 million in the quarter, an increase of 7% from the year-ago period. Sales of Namenda, a treatment for moderate and severe Alzheimer's disease, increased 24% to $192.9 million year over year. Forest said that product wholesalers held less inventory of both Lexapro and Namenda at the end of the September quarter, which negatively impacted combined sales by roughly $18 million.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV